内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

NICE指南：原发性甲状旁腺功能亢进的诊断，评估和初步治疗

2019-06-05 国家卫生和护理研究所（NICE） NICE

甲状旁腺功能亢进

本指南涵盖了原发性甲状旁腺功能亢进症的诊断，评估和管理。 它旨在改善对此病的认识和治疗，减少长期并发症并改善生活质量。

中文标题：

NICE指南：原发性甲状旁腺功能亢进的诊断，评估和初步治疗

英文标题：

Hyperparathyroidism (primary): diagnosis, assessment and initial management

发布机构：

国家卫生和护理研究所（NICE）

发布日期：

2019-06-05

简要介绍：

本指南涵盖了原发性甲状旁腺功能亢进症的诊断，评估和管理。 它旨在改善对此病的认识和治疗，减少长期并发症并改善生活质量。

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=1084b1c002058e62, title=NICE指南：原发性甲状旁腺功能亢进的诊断，评估和初步治疗, enTitle=Hyperparathyroidism (primary): diagnosis, assessment and initial management, guiderFrom=NICE, authorId=0, author=, summary=本指南涵盖了原发性甲状旁腺功能亢进症的诊断，评估和管理。 它旨在改善对此病的认识和治疗，减少长期并发症并改善生活质量。, cover=, journalId=0, articlesId=null, associationId=1435, associationName=国家卫生和护理研究所（NICE）, associationIntro=, copyright=0, guiderPublishedTime=Wed Jun 05 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">本指南涵盖了原发性甲状旁腺功能亢进症的诊断，评估和管理。</span> <span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="1">它旨在改善对此病的认识和治疗，减少长期并发症并改善生活质量。</span></span></p>, tagList=[TagDto(tagId=889, tagName=甲状旁腺功能亢进)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=30, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2892, appHits=341, showAppHits=0, pcHits=424, showPcHits=2551, likes=2, shares=24, comments=21, approvalStatus=1, publishedTime=Mon Feb 15 22:55:30 CST 2021, publishedTimeString=2019-06-05, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Sat Feb 13 20:26:54 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 11:02:38 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1084264, encodeId=16ef1084264e4, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5710484, createdName=ms8000000908018201, createdTime=Sat Dec 25 22:19:22 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069622, encodeId=fd6f10696228f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:31 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069016, encodeId=97a91069016d7, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210122/3915bce46e9f4e3583a864594be7db87/7ec44c1abec1427ba762db73d33661b5.jpg, createdBy=b5c75435171, createdName=Learner-Z, createdTime=Wed Nov 10 17:04:03 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997262, encodeId=caf699e26258, content=非常喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4122551501, createdName=125427e5m41暂无昵称, createdTime=Wed Jul 07 17:48:04 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965771, encodeId=5ec8965e7169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d315434138, createdName=lilyhua2020, createdTime=Sat May 15 09:38:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-12-25 ms8000000908018201

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1084264, encodeId=16ef1084264e4, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5710484, createdName=ms8000000908018201, createdTime=Sat Dec 25 22:19:22 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069622, encodeId=fd6f10696228f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:31 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069016, encodeId=97a91069016d7, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210122/3915bce46e9f4e3583a864594be7db87/7ec44c1abec1427ba762db73d33661b5.jpg, createdBy=b5c75435171, createdName=Learner-Z, createdTime=Wed Nov 10 17:04:03 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997262, encodeId=caf699e26258, content=非常喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4122551501, createdName=125427e5m41暂无昵称, createdTime=Wed Jul 07 17:48:04 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965771, encodeId=5ec8965e7169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d315434138, createdName=lilyhua2020, createdTime=Sat May 15 09:38:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-11-12 feifei2511

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1084264, encodeId=16ef1084264e4, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5710484, createdName=ms8000000908018201, createdTime=Sat Dec 25 22:19:22 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069622, encodeId=fd6f10696228f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:31 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069016, encodeId=97a91069016d7, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210122/3915bce46e9f4e3583a864594be7db87/7ec44c1abec1427ba762db73d33661b5.jpg, createdBy=b5c75435171, createdName=Learner-Z, createdTime=Wed Nov 10 17:04:03 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997262, encodeId=caf699e26258, content=非常喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4122551501, createdName=125427e5m41暂无昵称, createdTime=Wed Jul 07 17:48:04 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965771, encodeId=5ec8965e7169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d315434138, createdName=lilyhua2020, createdTime=Sat May 15 09:38:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-11-10 Learner-Z

    好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1084264, encodeId=16ef1084264e4, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5710484, createdName=ms8000000908018201, createdTime=Sat Dec 25 22:19:22 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069622, encodeId=fd6f10696228f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:31 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069016, encodeId=97a91069016d7, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210122/3915bce46e9f4e3583a864594be7db87/7ec44c1abec1427ba762db73d33661b5.jpg, createdBy=b5c75435171, createdName=Learner-Z, createdTime=Wed Nov 10 17:04:03 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997262, encodeId=caf699e26258, content=非常喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4122551501, createdName=125427e5m41暂无昵称, createdTime=Wed Jul 07 17:48:04 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965771, encodeId=5ec8965e7169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d315434138, createdName=lilyhua2020, createdTime=Sat May 15 09:38:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-07-07 125427e5m41暂无昵称

    非常喜欢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1084264, encodeId=16ef1084264e4, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae3e5710484, createdName=ms8000000908018201, createdTime=Sat Dec 25 22:19:22 CST 2021, time=2021-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069622, encodeId=fd6f10696228f, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:31 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069016, encodeId=97a91069016d7, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210122/3915bce46e9f4e3583a864594be7db87/7ec44c1abec1427ba762db73d33661b5.jpg, createdBy=b5c75435171, createdName=Learner-Z, createdTime=Wed Nov 10 17:04:03 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997262, encodeId=caf699e26258, content=非常喜欢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4122551501, createdName=125427e5m41暂无昵称, createdTime=Wed Jul 07 17:48:04 CST 2021, time=2021-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965771, encodeId=5ec8965e7169, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d315434138, createdName=lilyhua2020, createdTime=Sat May 15 09:38:17 CST 2021, time=2021-05-15, status=1, ipAttribution=)]
    2021-05-15 lilyhua2020

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

原发性甲状旁腺功能亢进症围手术期处理中国专家共识（2020版）

中华医学会外科学分会 · 2020-06-30